HBMCX
Price
$26.13
Change
-$0.13 (-0.50%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

HBMCX vs RPTIX

Header iconHBMCX vs RPTIX Comparison
Open Charts HBMCX vs RPTIXBanner chart's image
Hartford MidCap HLS IB
Price$26.13
Change-$0.13 (-0.50%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
HBMCX vs RPTIX Comparison Chart
Loading...
VS
HBMCX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBMCX is a StrongBuy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. HBMCX (861M). RPTIX pays higher dividends than HBMCX: RPTIX (0.18) vs HBMCX (0.00). HBMCX was incepted earlier than RPTIX: HBMCX (25 years) vs RPTIX (9 years). HBMCX is a more actively managed with annual turnover of: 40.00 vs. RPTIX (21.70). HBMCX has a lower initial minimum investment than RPTIX: HBMCX (0) vs RPTIX (500000). RPTIX annual gain was more profitable for investors over the last year : 14.81 vs. HBMCX (13.71). RPTIX return over 5 years is better than : 15.09 vs. HBMCX (-24.92).
HBMCXRPTIXHBMCX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence25 years9 years-
Gain YTD1.9519.12721%
Front LoadN/AN/A-
Min. Initial Investment0500000-
Min. Initial Investment IRAN/AN/A-
Net Assets861M31.4B3%
Annual Yield % from dividends0.000.18-
Returns for 1 year13.7114.8193%
Returns for 3 years-29.89-13.57220%
Returns for 5 years-24.9215.09-165%
Returns for 10 years-26.29N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp